Skip To Main Content
Pere Barba on Muck Rack

Pere Barba

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, Dialnet - Universidad de La Rioja, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pere

Contact Pere, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis - Bone Marrow Transplantation

|
By Víctor Navarro Verified, Gloria Iacoboni, Cecilia Carpio, Samantha Feijóo, Francesc Bosch, Guillermo Villacampa, Pere Barba, Sergi Camarillas, Mario Sánchez-Salinas
| Nature Verified
Abstract Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a major challenge, with many patients experiencing relapse after an initial remission.
Open in Who Shared Issue with article?

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma | Blood Cancer Journal

|
By Adam S. Kittai, Antonio Gutierrez, Antonio Gutiérrez, Alejandro Martín García-Sancho, Monica D. Mead, Pere Barba, Catherine Thieblemont, Pier Luigi Zinzani
| Nature Verified
The rationale for this project arises from some considerations. Clinical trials often use surrogate endpoints (response rates) rather than direct measurement of benefit (survivals) as primary objective of the study.
Open in Who Shared Issue with article?

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) an

|
By Pere Barba, Lucia López-Corral, Joaquín Martínez-López, Pim Mutsaers, Friso G. Calkoen, Jaap van Doesum, Johan Maertens, Keith Wilson, František Folber, Jürgen Finke, Nicolaus Kröger, Marie José Kersten, Emma Nicholson
| Nature Verified
Abstract COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT.
Open in Who Shared Issue with article?
See all 8 licensed articles (9 Total)